EGFR and cancer: In the same study, low-coverage whole genome sequencing (WGS) confirmed the variety of CNA from CGH studies, affecting known cancer driver genes, such as CDKN2A, CCND1, CCNE1, EGFR, EPHA3, EPHB1, FGFR1, JUN, NF1, RB1, RET, and TP53; interestingly, higher grade areas of the same tumor showed novel emerged focal amplifications including CCNE1, KIT, EGFR, RET, BRAF, NTRK2 compared with the respective lower grade areas.